304 related articles for article (PubMed ID: 31454530)
21. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
[TBL] [Abstract][Full Text] [Related]
22. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
[TBL] [Abstract][Full Text] [Related]
23. Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM via a T Cell-Dependent Mechanism.
Elsadek NE; Emam SE; Abu Lila AS; Shimizu T; Ando H; Ishima Y; Ishida T
Biol Pharm Bull; 2020; 43(9):1393-1397. PubMed ID: 32879214
[TBL] [Abstract][Full Text] [Related]
24. Suppression in mice of immunosurveillance against PEGylated liposomes by encapsulated doxorubicin.
Yahuafai J; Asai T; Nakamura G; Fukuta T; Siripong P; Hyodo K; Ishihara H; Kikuchi H; Oku N
J Control Release; 2014 Oct; 192():167-73. PubMed ID: 25041998
[TBL] [Abstract][Full Text] [Related]
25. High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies.
Talkington AM; McSweeney MD; Zhang T; Li Z; Nyborg AC; LaMoreaux B; Livingston EW; Frank JE; Yuan H; Lai SK
J Control Release; 2021 Oct; 338():804-812. PubMed ID: 34481925
[TBL] [Abstract][Full Text] [Related]
26. Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture.
Lin YC; Chen BM; Tran TTM; Chang TC; Al-Qaisi TS; Roffler SR
J Control Release; 2023 Feb; 354():354-367. PubMed ID: 36641121
[TBL] [Abstract][Full Text] [Related]
27. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies.
Chen BM; Cheng TL; Roffler SR
ACS Nano; 2021 Sep; 15(9):14022-14048. PubMed ID: 34469112
[TBL] [Abstract][Full Text] [Related]
28. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Kikuchi H; Ishihara H
Int J Pharm; 2014 Dec; 476(1-2):205-12. PubMed ID: 25280884
[TBL] [Abstract][Full Text] [Related]
29. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
[TBL] [Abstract][Full Text] [Related]
30. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin.
Cho HJ; Yoon IS; Yoon HY; Koo H; Jin YJ; Ko SH; Shim JS; Kim K; Kwon IC; Kim DD
Biomaterials; 2012 Feb; 33(4):1190-200. PubMed ID: 22074664
[TBL] [Abstract][Full Text] [Related]
31. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
32. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance.
Shiraishi K; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Sanada Y; Mochizuki S; Sakurai K; Yokoyama M
J Control Release; 2016 Jul; 234():59-67. PubMed ID: 27164541
[TBL] [Abstract][Full Text] [Related]
33. Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients.
Miao G; He Y; Lai K; Zhao Y; He P; Tan G; Wang X
J Control Release; 2023 Nov; 363():12-26. PubMed ID: 37717659
[TBL] [Abstract][Full Text] [Related]
34. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
Koide H; Asai T; Hatanaka K; Akai S; Ishii T; Kenjo E; Ishida T; Kiwada H; Tsukada H; Oku N
Int J Pharm; 2010 Jun; 392(1-2):218-23. PubMed ID: 20227473
[TBL] [Abstract][Full Text] [Related]
35. Accelerated Clearance of Ultrasound Contrast Agents Containing Polyethylene Glycol is Associated with the Generation of Anti-Polyethylene Glycol Antibodies.
Fix SM; Nyankima AG; McSweeney MD; Tsuruta JK; Lai SK; Dayton PA
Ultrasound Med Biol; 2018 Jun; 44(6):1266-1280. PubMed ID: 29602540
[TBL] [Abstract][Full Text] [Related]
36. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
[TBL] [Abstract][Full Text] [Related]
37. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
38. Detection of Pre-Existing Antibodies to Polyethylene Glycol and PEGylated Liposomes in Human Serum.
Neun BW; Dobrovolskaia MA
Methods Mol Biol; 2024; 2789():185-192. PubMed ID: 38507004
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.
Northfelt DW; Martin FJ; Working P; Volberding PA; Russell J; Newman M; Amantea MA; Kaplan LD
J Clin Pharmacol; 1996 Jan; 36(1):55-63. PubMed ID: 8932544
[TBL] [Abstract][Full Text] [Related]
40. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
